CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellularae complex, M. chelonae, and M. fortuitum.
A 7H9 broth microdilution method against CI-960, sparfloxacin, WIN57273, ciprofloxacin, norfloxacin, isepamicin, amikacin, kanamycin, ethambutol, isoniazid, and rifampin was used to test 35 Mycobacterium avium-intracellulare complex (MAI) and five M. chelonae-fortuitum strains. The majority of MAI isolates were inhibited by all tested compounds, with sparfloxacin (MIC90, 0.5 micrograms/ml) being the most active among the fluoroquinolones; isepamicin (MIC90, 4 micrograms/ml), the most potent aminoglycoside; and isoniazid, rifampin, and ethambutol also demonstrating some degree of activity. Mycobacterium chelonae strains were resistant to all drugs except ciprofloxacin (MIC50, 1 microgram/ml). Mycobacterium fortuitum isolates were generally susceptible, especially to the newer fluoroquinolones.
Barrett
M S
MS
Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City 52242.
Jones
R N
RN
Erwin
M E
ME
Koontz
F P
FP
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D024841:Fluoroquinolones; D005839:Gentamicins / Q000494:pharmacology; D006801:Humans; D008826:Microbial Sensitivity Tests; D015269:Mycobacterium avium Complex / Q000187:drug effects*; D016926:Mycobacterium chelonae / Q000187:drug effects*; D009170:Nontuberculous Mycobacteria / Q000187:drug effects*; D015363:Quinolones / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D005839:Gentamicins; D015363:Quinolones; C062556:Win 57273; C057477:clinafloxacin; C016927:isepamicin; C061363:sparfloxacin